Firefly Neuroscience, Inc.
AIFF Nasdaq· Services-Prepackaged Software
Last close · Oct 23, 2026
$0.92
KIRA · Stoqly’s AI analyst, in plain words
- Firefly Neuroscience, Inc. had $1.1M of revenue in fiscal 2025, up 957.4% on the year before. Over five years, revenue changed −39.3% a year on average.
- Its operating margin was −775.5%, up 8,533.8 pts: of every 100 in sales, about −775 is left after running the business.
- Firefly Neuroscience, Inc. lost $19.9M in fiscal 2025.
Market cap
—
P/E
—
Revenue
$1.1M
Net income
−$19.9M
Free cash flow
—
Operating margin
−775.5%
Firefly Neuroscience, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+957.4%
Yes. Sales grew 957.4% last year.
Does it make a profit?
−1,741.0%
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
What Firefly Neuroscience, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- FIREFLY NEUROSCIENCE, INC.
- CIK
- 0000803578
Firefly Neuroscience, Inc. · AIFF
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $15.0M | $12.0M | $0.5M | $0.1M | $1.1M |
| Revenue growth | 8.1% | −20.0% | −95.9% | −78.3% | 957.4% |
| Gross margin | 24.1% | 23.8% | 525.0% | 100.0% | 56.5% |
| Operating margin | −17.5% | −45.1% | −618.1% | −9,309.3% | −775.5% |
| Net income | −$1.1M | −$17.8M | −$2.6M | −$10.5M | −$19.9M |
| Net margin | −7.5% | −147.7% | −522.7% | −9,685.2% | −1,741.0% |
| Diluted EPS | −$0.09 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$0.7M | −$6.0M | −$2.2M | −$6.2M | −$8.2M |
| Capital expenditure | $0.1M | $0.5M | $0.0M | — | — |
| Free cash flow | −$0.8M | −$6.5M | −$2.2M | — | — |
| FCF margin | −5.4% | −54.5% | −436.1% | — | — |
| Share count change | 4.4% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $4.9M | $0.7M | $0.7M | $1.8M | $2.7M |
| Shareholders' equity | $17.4M | −$2.2M | $0.1M | −$0.4M | $7.6M |
| Current ratio | 3.5x | 0.7x | 0.9x | 0.5x | 1.4x |
| Interest coverage | −70.4x | −66.4x | −29.8x | — | — |
| Returns and quality | |||||
| Return on equity | −11.9% | −233.4% | — | — | −547.6% |
| Return on tangible equity | −62.6% | — | — | — | −1,532.2% |
| Piotroski F-score | 3 | 2 | 4 | 1 | 4 |
| Altman Z'' | 1.8 | −18.7 | −103.1 | −79.8 | −36.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Firefly Neuroscience, Inc. · AIFF
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.92 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0000803578). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.